The natural design and coupling of biological structures are the root of realizing the high
strength, toughness, and unique functional properties of biomaterials. Advanced architecture …

Bone fragility is the determinant of the increased risk of minimal trauma fracture and must be
treated with a multimodal approach that includes pharmacological therapy, physical …

Bone fragility is the susceptibility to fracture even for common loads because of structural,
architectural, or material alterations of bone tissue that result in poor bone strength. In …

Severe osteoporosis is often treated with one of three Food and Drug Administration (FDA)-
approved osteoanabolics. These drugs act by (1) parathyroid hormone (PTH) receptor …

Romosozumab treatment in women with postmenopausal osteoporosis increases bone
formation while decreasing bone resorption, resulting in large BMD gains to reduce fracture …

Osteoporosis, characterized by a reduction in bone mineral density, represents a prevalent
skeletal disorder with substantial global health implications. Conventional therapeutic …

Materials and methods Data for patients initiating romosozumab or other antiosteoporotic
medications between March 01, 2018, and May 31, 2022, were extracted from the Medical …

This retrospective study compared the efficacy of anabolic agents (romosozumab and
teriparatide) with that of alendronate in preventing subsequent vertebral body fractures …

Sclerostin inhibits osteoblast activity by hampering activation of the canonical Wnt signaling
pathway and simultaneously stimulates osteoclastogenesis through upregulation of the …

The progress in research has improved the understanding of the epidemiology and
pathogenesis of osteoporosis and bone disorders in general. Metabolic bone changes have …